2024年11月1日 · Antag Therapeutics是一家处于临床阶段的生物制药公司，专注于通过GIP受体拮抗剂开发新型肥胖及心脏代谢疾病的治疗方案。作为探索GIP受体拮抗剂潜力的先锋，该公司致力于推动科学进步和改善患者健康，提供针对未满足医疗需求的突破性解决方案。

2017年12月4日 · At Antag Therapeutics, we are dedicated to transforming the treatment landscape by developing innovative GIPR antagonist therapies to combat obesity and offer new solutions for patients worldwide. Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found naturally in the human body

Antag Therapeutics是一家处于临床阶段的生物制药公司，专注于通过GIP受体拮抗剂开发新型肥胖及心脏代谢疾病的治疗方案。 作为探索GIP受体拮抗剂潜力的先锋，该公司致力于推动科学进步和改善患者健康，提供针对未满足医疗需求的突破性解决方案。

Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn

2024年12月4日 · Antag Therapeutics, a seven-year-old Danish startup investigating a hotly debated approach to treating obesity, has raised 80 million euros, or about $84 million, to advance its first weight loss drug into clinical testing.

2024年12月4日 · GLP-1-based therapies have revolutionized obesity management, but for some patients can cause tolerability issues, loss of muscle mass, and suboptimal weight-loss. This highlights the need for...

AT-7687: 一种GIPR 拮抗剂药物，由Antag Therapeutics ApS (Antag Therapeutics ApS)公司最早进行研发，目前全球最高研发状态为临床申请批准，作用机制: GIPR 拮抗剂(肠抑胃肽受体 拮抗剂)，治疗领域: 内分泌与代谢疾病，在研适应症: 肥胖，在研机构: Antag Therapeutics ApS。

2024年12月6日 · Following the FDA’s October 2024 clearance of Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, the Copenhagen-based biopharmaceutical company has announced the successful closing of an €80 million Series A financing round.

2024年12月5日 · Antag says this flexibility in dosing provides multiple advantages over competing GIPR blockers such as antibodies directly conjugated to GLP-1. These include the ability to drug each target for maximal efficacy and tolerability. In addition, AT-7687 also can be used as a single agent in the maintenance setting.

2017年6月26日 · Antag Therapeutics ApS is founded on decades of seminal research focused on peptide-based drugs and dietary-related metabolic diseases from Professors Mette M. Rosenkilde and Jens J. Holst at the University of Copenhagen.